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We present six cases of central retinal artery occlusion (CRAO) and central retinal vein occlusion 
(CRVO) that we recently treated with hyperbaric oxygen (HBO2). Patients in three of the six cases, 
including the CRVO case, experienced near to complete restoration of their vision. Another case 
had marked improvement. Our findings are similar to other case studies with approximately 65-70% 
improvement in patients treated for CRAO. Physicians should be aware that rapid referral of CRAO 
and CRVO patients to HBO2 is efficacious. Such patients should be placed on 100% oxygen by non-
rebreather mask as soon as the diagnosis is suspected, pending transportation to HBO2. [Clin Pract 
Cases Emerg Med. 2019;3(4):338–340.]
INTRODUCTION
Central retinal artery occlusion (CRAO) is an emergent 
condition, typically presenting as sudden painless visual 
loss.1 Risk factors for CRAO include giant cell arteritis, 
atherosclerosis, atrial fibrillation, and thromboembolic disease. 
Permanent eye injury usually occurs after two hours of the 
occlusive event. CRAO is caused by embolism in the central 
retinal artery. Branch artery occlusion can also occur in the 
smaller (ciliary) branches of this artery. The occlusion leads to 
ischemia in the retina leading to pallor and the classic finding 
of “cherry red” macula due to increased visualization of the 
macula through the retina.1 
Treatment methods include ocular massage to dislodge 
the embolus by creating a pressure differential, medications 
to decrease intraocular pressure (IOP), increasing partial 
pressure of carbon dioxide to cause retinal artery dilation 
with carbogen, a mixture of 95% oxygen and 5% carbon 
dioxide, intra-arterial fibrinolysis or systemic thrombolytics, 
and in extreme cases anterior chamber paracentesis to create 
an acute drop in IOP to dislodge the embolism. None of 
these interventions have demonstrated significant success.2 
Recently hyperbaric oxygen (HBO2) has been approved by 
the Undersea and Hyperbaric Medical Society (UHMS) for 
treatment of CRAO due to evidence of significant efficacy.3
Central retinal vein occlusion (CRVO) has similar 
presenting symptoms and pathology to CRAO. CRVO is acute 
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monocular vision loss from occlusions of the central retinal 
vein resulting in edema and ischemia to the retina. This occurs 
due to the central retinal artery and vein being the principal 
blood supply and drainage for the retina. Risk factors include 
hypertension (HTN), diabetes mellitus (DM), glaucoma and 
hypercoagulable conditions.4 Treatment considerations are 
similar to CRAO; however, anti-vascular endothelial growth 
factor medications are sometimes indicated to prevent macular 
edema and neovascularization, which can lead to glaucoma. 
HBO2 has been a proposed treatment modality for CRVO due 
to the similarities in pathology when compared to CRAO. 
In this article we will discuss six cases, four of which 
were CRAO, one a branch retinal artery occlusion (BRAO), 
and one of CRVO. All were treated with HBO2 with 
improvement. The protocols used in these cases are from 
the 13th edition of the UHMS HBO2 therapy guidelines. 
Treatments were generally 90 minutes at prescribed pressure, 
which was 2.5-2.8 atmospheres absolute with air breaks and 
additional time for compression and decompression.  
CASE SERIES
Case One
Patient A, a 73-year-old female with a past medical 
history of coronary artery disease (CAD), congestive heart 
failure (CHF), atrial fibrillation, aortic and mitral valve 
replacement, HTN, hyperlipidemia (HPL), and DM, presented 
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What do we already know about this clinical 
entity? 
Central retinal artery occlusion (CRAO) is 
an emergent condition. None of the generally 
suggested treatment interventions have 
demonstrated significant success until the 
recent use of hyperbaric oxygen (HBO2 ).
What makes this presentation of disease 
reportable? 
We report six cases, four CRAO, one branch 
retinal artery occlusion, and one central 
retinal vein occlusion with varied results and a 
discussion of the rationale for efficacy.
What is the major learning point? 
HBO2 may salvage vision loss in retinal 
artery and vein occlusions.  
How might this improve emergency 
medicine practice? 
Rapid identification and referral to 
hyperbaric therapy is important to improve 
the chances of visual recovery in retinal 
artery and vein occlusions.
from an outside facility with acute painless monocular vision 
loss when bending over to pick something up. The patient 
was initially evaluated by an ophthalmologist and diagnosed 
with CRAO. Visual acuity (VA) in the right eye oculus 
dextrus (OD) was not testable due to blindness; left eye oculus 
sinister (OS) had baseline visual acuity of 20/25. The patient 
underwent HBO2 treatment within 13 hours of last known 
normal time and tolerated five treatments with improvement 
in the peripheral visual field; however, the central visual field 
defect remained.
Case Two
Patient B, a 59-year-old male with a past medical history 
of HTN, DM, and aortic stenosis with mechanical valve 
replacement, was admitted for CRAO diagnosed at an outside 
facility. He underwent HBO2 treatment within 23 hours of 
initial injury. VA of OD was zero, OS 20/25. The patient 
underwent five HBO2 treatments per protocol and regained 
some peripheral vision during the hospitalization and upon 
discharge was able to count fingers (Table).
Case Three
Patient C, a 39-year-old female with a past medical 
history of anxiety and hypothyroidism, presented with 
left sided retrobulbar headache. She was diagnosed with 
paraclinoid internal carotid artery aneurysm and underwent 
pipeline embolization with full symptomatic improvement and 
normal visual acuity upon discharge. She presented three days 
later and was found to have a left BRAO with initial visual 
acuity of 20/100 in the affected eye. She underwent HBO2 
therapy within 10 hours of initial insult. After five HBO2 
treatments her visual acuity returned to baseline (Table).
Case Four
Patient D, a 73-year-old male, presented with a history 
of head injury at age 11 causing blindness in his left eye, 
peripheral vascular disease, HTN, chronic obstructive 
pulmonary disease, and DM. He had acute onset of visual 
loss in his right eye after waking from a nap. He was 
diagnosed with CRAO at an outside facility. His initial visual 
acuity could not be obtained due to blindness in both eyes. 
After three HBO2 treatments his visual acuity improved to 
20/50 OD. The patient was unable to tolerate further HBO2 
treatments due to confinement anxiety (Table).
Case Five
Patient E, a 62-year-old female with a past medical 
history of HTN, carotid artery stenosis, CAD, and tobacco 
abuse, presented as a transfer from an outside facility due 
to right sided painless visual loss. HBO2 treatment was 
initiated 23 hours after initial symptom onset. The patient was 
only able to tolerate two and a half HBO2 treatments due to 
confinement anxiety. She was pretreated with lorazepam on 
her second HBO2 treatment unsuccessfully, and unfortunately 
declined further treatment. Visual acuity had improved from 
light perception to ability to visualize hand motion (Table).
Case Six
Our final patient F, a 46-year-old male, presented with 
acute painless monocular visual loss in the left eye. Symptoms 
started 48 hours prior to presentation. This patient had a past 
medical history significant for HTN, DM, and HLD, and 
Sjogren’s syndrome with previous CRVO of the right eye 
with blindness. He was found to have a new CRVO in his left 
eye. He underwent 10 HBO2 treatments with near-complete 
improvement in visual acuity to 20/30 at discharge (Table).
DISCUSSION
The above-mentioned cases had improvement in vision 
with HBO2 therapy for vaso-occlusive injury to the eye. 
Patients in three out of the six cases experienced near to 
complete restoration of their vision. Another case had marked 
improvement. Confinement anxiety was an issue in two 
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Patient
Hours from 
vision loss 
to HBO2
Number of 
HBO2 
treatments Outcome Comment
A 13 5 Some peripheral field improvement only
B 23 5 Zero vision to finger counting
C 10 5 Complete resolution Branch retinal artery occlusion
D 9 3 Improved to 20/50 Confinement anxiety
E 23 2.5 From light perception to ability to visualize hand motion Confinement anxiety
F 48 10 Near-complete resolution 20/30 Central retinal vein occlusion
HBO2, hyperbaric oxygen.
Table. Summary of cases of sudden monocular blindness treated with hyperbaric oxygen.
cases. Our findings are similar to other case studies with 
approximately 65-70% improvement in patients treated for 
CRAO3 with an excellent result in CRVO.  
While the eye is primarily supplied by the retinal artery, 
there is also some contribution by the choroidal vessels 
(ciliary arteries). Under normal circumstances, the choroidal 
supply is inadequate to support the retina; however, under 
hyperbaric conditions the choroidal circulation can supply 
the retina with adequate oxygen. This can allow the retina to 
survive until the retinal arterial (or venous) occlusion resolves 
via intrinsic thrombolytic mechanisms. HBO2 also ameliorates 
subsequent reperfusion effects and edema.3
CONCLUSION
Hyperbaric oxygen has established a clear efficacy for 
treating CRAO. There have been multiple case reports with 
promising outcomes for CRVO as well.4-6 Both emergency 
physicians and ophthalmologists should be aware that rapid 
referral of CRAO and CRVO patients to HBO2 therapy is 
efficacious. Such patients should be placed on 100% oxygen 
by non-rebreather mask as soon as the diagnosis is suspected7 
pending transportation to HBO2.
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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